SNPMiner Trials (Home Page)
Report for SNP rs751402
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Effect of Genetic Polymorphisms on Clinical Outcome of Platinum Based Chemotherapy in Non-Small Cell Lung Cancer Patients
This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients
NCT03154242 Carcinoma, Non-Small-Cell Lung MeSH: Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO: Neoplasm of the lung Non-small cell lung carcinoma
Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients Progression-free survival (PFS).
Primary Outcomes
Description: It's defined as the time from day 1 of chemotherapy to the day of documented disease progression or death from any cause.
Measure: Progression-free survival (PFS) Time: From the date of starting the chemotherapy until the date of documented disease progression or date of death from any cause assessed up to 12 months